Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thiamine
Drug ID BADD_D02197
Description Thiamine or thiamin, also known as vitamin B1, is a colorless compound with the chemical formula C12H17N4OS. It is soluble in water and insoluble in alcohol. Thiamine decomposes if heated. Thiamine was first discovered by Umetaro Suzuki in Japan when researching how rice bran cured patients of Beriberi. Thiamine plays a key role in intracellular glucose metabolism and it is thought that thiamine inhibits the effect of glucose and insulin on arterial smooth muscle cell proliferation. Thiamine plays an important role in helping the body convert carbohydrates and fat into energy. It is essential for normal growth and development and helps to maintain proper functioning of the heart and the nervous and digestive systems. Thiamine cannot be stored in the body; however, once absorbed, the vitamin is concentrated in muscle tissue.
Indications and Usage For the treatment of thiamine and niacin deficiency states, Korsakov's alcoholic psychosis, Wernicke-Korsakov syndrome, delirium, and peripheral neuritis.
Marketing Status approved; investigational; nutraceutical; vet_approved
ATC Code Not Available
DrugBank ID DB00152
KEGG ID D08580
MeSH ID D013831
PubChem ID 1130
TTD Drug ID D06PQT
NDC Product Code Not Available
UNII X66NSO3N35
Synonyms Thiamine | Thiamin | Vitamin B1 | Aneurin | Vitamin B 1 | Thiamine Mononitrate | Mononitrate, Thiamine
Chemical Information
Molecular Formula C12H17N4OS+
CAS Registry Number 70-16-6
SMILES CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.0120.000947%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001--Not Available
Asthenia08.01.01.001--Not Available
Circulatory collapse24.06.02.001--Not Available
Confusional state19.13.01.001; 17.02.03.0050.001421%
Cyanosis24.03.01.007; 22.02.02.007; 23.06.04.005; 02.11.04.004--
Decreased activity19.11.01.002; 08.01.01.0060.000947%Not Available
Delirium19.13.02.0010.000947%
Delusional perception19.10.05.0030.000947%Not Available
Depressed level of consciousness17.02.04.0020.000947%
Depressed mood19.15.02.0010.000947%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.001421%
Drooling17.02.05.0050.000947%Not Available
Drug interaction08.06.03.0010.000947%Not Available
Dysarthria17.02.08.001; 19.19.03.0010.001421%
Dyspnoea22.02.01.004; 02.11.05.0030.003316%
Erythema23.03.06.0010.001421%Not Available
Feeling hot08.01.09.009--Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.0020.000947%
Haemoglobin13.01.05.018--Not Available
Hallucination19.10.04.0030.001421%
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000947%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypotonia15.05.04.008; 17.05.02.0020.001421%Not Available
Malaise08.01.01.0030.000947%
Nausea07.01.07.0010.001421%
Obsessive-compulsive disorder19.06.05.0020.000947%Not Available
Pruritus23.03.12.0010.002084%
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene